Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta

16 Jul 2020

Abstract excerpt

In recent years, a number of drugs have been approved for the treatment of cystic fibrosis (CF). Among them, newly released Trikafta, a combination of 3 drugs (VX-661/VX-445/VX-770), holds great promise to radically improve the quality of life for a large portion of patients with CF carrying 1 copy of F508del, the most frequent CF transmembrane conductance regulator (CFTR) mutation. Currently available...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Cystic Fibrosis Research Advances
Share to Neonatal Respiratory Health Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32673287
DOI: 10.1172/jci.insight.138722

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including TrikaftaPMID 32673287Read ↗

Cystic fibrosis cell models for high-throughput analysis and drug screening.Semantic proximity Read ↗

Robust W1282X-CFTR rescue by a small molecule GSPT1 degraderSemantic proximity Read ↗

An Innovative Lipidomic Workflow to Investigate the Lipid Profile in a Cystic Fibrosis Cell Line.Semantic proximity Read ↗

The Cystic Fibrosis treatment, Trikafta, affects growth, viability, and cell wall of <i>Aspergillus fumigatus</i> biofilmsSemantic proximity Read ↗

Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.Semantic proximity Read ↗

The combination elexacaftor/tezacaftor/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner.Semantic proximity Read ↗

Lipidome Alterations Induced by Cystic Fibrosis, CFTR Mutation, and Lung Function.Semantic proximity Read ↗

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.Semantic proximity Read ↗

Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells.Semantic proximity Read ↗

L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patientsSemantic proximity Read ↗

Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor (ETI) suggest benefits beyond improved CFTR channel functionSemantic proximity Read ↗

Beyond Kaftrio : mechanistic insights to maximize N1303K-CFTR rescueSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.